Ysios Capital Investors
Ysios Capital is a leading life sciences investor financing highly innovative companies worldwide fostering a positive impact on patients and society. ... The company’s lead product, TD139, is an inhaled galectin-3 inhibitor in Phase II/III studies for the treatment of idiopathic pulmonary fibrosis (IPF). Galecto is located in Copenhagen ...
Headquarters:
Spain
Number Of Exists:
13
Founded Date:
2008-01-01
Employee Number:
11-50
Investment Stage:
Early Stage Venture, Late Stage Venture, Venture
Investor Type:
Technology - oriented Investor with Venture Investment Focus
Technology:
N/A
Funding Status:
N/A
Industry:
Asset Management